Antibiotics Open a Door. This Yeast Helps Close It.

Vital Yogurts — The Science

Finishing a round of antibiotics feels like a finish line. For about one in eight people recovering from a Clostridioides difficile infection, it turns out to be the starting gun for a relapse.

C. difficile is not a random pathogen. It's an opportunist — one that normally exists in the gut without causing problems, held in balance by the broader microbial community. Antibiotics change that balance dramatically. A course of vancomycin — the standard treatment for CDI — is effective at clearing the infection, but it's also rough on the surrounding microbial landscape. The gut comes out of treatment depleted, and the question isn't whether C. difficile will still be present. It's whether anything is left to keep it in check. Often, the answer is: not much.

This is the mechanism behind recurrence, and it's why CDI has one of the highest reinfection rates of any gut infection. Clearing the primary episode is achievable. Staying clear is harder.

A 2025 randomized controlled trial published in Scientific Reports enrolled 120 adults with confirmed C. difficile infection — all receiving vancomycin — and randomly assigned half to add Saccharomyces boulardii to their treatment, and half to receive a placebo. The results were significant. The global cure rate was 96.6% with S. boulardii, compared to 85.3% with placebo. But the 30-day recurrence data is what stands out: 1.7% relapse rate in the yeast group, versus 13.1% in the placebo group. Nearly an 8-fold reduction.

There were no differences in adverse events between groups. The yeast appears to be both effective and well-tolerated as an adjunct — not a replacement for antibiotic therapy, but a meaningful addition to it.

The mechanism is more direct than "restoring the microbiome." S. boulardii produces serine proteases — enzymes that physically cleave C. difficile toxins A and B before they can bind to intestinal cells and cause damage. It also competes directly for the receptor sites C. difficile uses to colonize the gut, making it harder for the pathogen to re-establish itself once treatment ends.

Finger Lakes from Vital Yogurts contains Saccharomyces boulardii — the same culture studied in this trial. If you're moving through or recovering from an antibiotic course, this is the research that makes Finger Lakes worth having on hand during that window. The evidence here is specific: not general gut support, but a well-documented, mechanistically grounded response to a defined vulnerability. For the full science — mechanisms, data tables, and protocol notes — read our deep dive →

This post is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your diet or supplement routine.